This therapy is the treatment approach commonly seen in the management of intrahepatic cholangiocarcinoma, which is associated with a high incidence of fibroblast growth factor receptor (FGFR) fusion mutations and dehydrogenase isocitrate (IDH)-1 and 2 mutations [4]. Here, IDH1 is linked to intrahepatic cholangiocarcinoma.